Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") ...

AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...